The OlympiaN trial is evaluating pCR and event-free survival post neoadjuvant olaparib monotherapy versus in combination with durvalumab for high and low-risk patients with ER-negative/ER-low/HER2-negative breast cancer [65, 66]. Here, ESR1 is linked to breast carcinoma.